Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Laura Michaelis MD

Laura Michaelis MD profile photo picture

Chief, Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Hematology

Member of the Cancer Center

View Curriculum Vitae

Publications (58)

  • How I diagnose and treat thrombocytopenia in geriatric patients. (Foy P, Friedman KD, Michaelis LC) Blood 2024 Jan 18;143(3):214-223 PMID: 37956435 SCOPUS ID: 2-s2.0-85180443922 11/13/2023    
  • Identifying Credible Sources of Health Information in Social Media: Phase 2-Considerations for Non-Accredited Nonprofit Organizations, For-Profit Entities, and Individual Sources. (Burstin H, Curry S, Ranney ML, Arora V, Wachler BB, Chou WS, Correa R, Cryer D, Dizon D, Flores EJ, Harmon G, Jain A, Johnson K, Laine C, Leininger L, McMahon G, Michaelis L, Minhas R, Mularski R, Oldham J, Padman R, Pinnock C, Rivera J, Southwell B, Villarruel A, Wallace K) NAM Perspect 2023;2023 PMID: 37916063 PMCID: PMC10617996 11/02/2023    
  • Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts. (Shallis RM, Daver N, Altman JK, Komrokji RS, Pollyea DA, Badar T, Bewersdorf JP, Bhatt VR, de Botton S, de la Fuente Burguera A, Carraway HE, Desai P, Dillon R, Duployez N, El Chaer F, Fathi AT, Freeman SD, Gojo I, Grunwald MR, Jonas BA, Konopleva M, Lin TL, Mannis GN, Mascarenhas J, Michaelis LC, Mims AS, Montesinos P, Pozdnyakova O, Pratz KW, Schuh AC, Sekeres MA, Smith CC, Stahl M, Subklewe M, Uy GL, Voso MT, Walter RB, Wang ES, Zeidner JF, Žučenka A, Zeidan AM) Lancet Haematol 2023 Sep;10(9):e767-e776 PMID: 37572683 SCOPUS ID: 2-s2.0-85169017350 08/13/2023       6 Citations
  • Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemotherapy. (Taylor S, Murthy GSG, Runaas L, Michaelis LC, Carlson K, Atallah EL, Abedin SM) Leuk Res 2023 Sep;132:107348 PMID: 37423073 SCOPUS ID: 2-s2.0-85164434355 07/10/2023    
  • PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis. (Moyo TK, Kishtagari A, Villaume MT, McMahon B, Mohan SR, Stopczynski T, Chen SC, Fan R, Huo Y, Moon H, Tang Y, Bejan CA, Childress M, Anderson I, Rawling K, Simons RM, Moncrief A, Caza R, Dugger L, Collins A, Dudley CV, Ferrell PB, Byrne M, Strickland SA, Ayers GD, Landman BA, Mason EF, Mesa RA, Palmer JM, Michaelis LC, Savona MR) Clin Cancer Res 2023 Jul 05;29(13):2375-2384 PMID: 37036505 SCOPUS ID: 2-s2.0-85160801595 04/11/2023       3 Citations
  • A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. (Assouline S, Michaelis LC, Othus M, Hay AE, Walter RB, Jacoby MA, Schroeder MA, Uy GL, Law LY, Cheema F, Sweet KL, Asch AS, Liu JJ, Moseley AB, Maher T, Kingsbury LL, Fang M, Radich J, Little RF, Erba HP) Leuk Lymphoma 2023 Feb;64(2):473-477 PMID: 36517990 PMCID: PMC10652187 SCOPUS ID: 2-s2.0-85144130323 12/16/2022       2 Citations
  • Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia. (Abedin SM, Badar T, Gauger K, Michaelis LC, Runaas L, Carlson KS, Murthy GG, Atallah E) Leuk Res 2022 Dec;123:106984 PMID: 36401944 SCOPUS ID: 2-s2.0-85141943453 11/20/2022       2 Citations
  • Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG. (Othus M, Thomas I, Wang X, Ariti C, Mehta P, Sydenham M, Hills RK, Burnett AK, Nand S, Assouline S, Michaelis LC, Erba HP, Russell N, Kerr KF, Walter RB, Dennis M) Leuk Lymphoma 2023 Jan;64(1):250-252 PMID: 36226777 PMCID: PMC10662133 SCOPUS ID: 2-s2.0-85139925753 10/14/2022    
  • A Pilot Clinical Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries in Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasm. (Dong A, Pan X, Lin CW, Huang YW, Krause H, Pan P, Baim A, Thomas MJ, Chen X, Yu J, Michaelis L, Liu P, Wang LS, Atallah E) J Cancer Prev 2022 Jun 30;27(2):129-138 PMID: 35864858 PMCID: PMC9271408 07/23/2022    
  • Prognostic impact of immunophenotypic aberrancies of blasts in lower risk myelodysplastic syndrome. (Corrao K, Rezwan S, Atallah E, Michaelis LC, Runaas L, Harrington AM, Abedin S) Leuk Res Rep 2022;17:100329 PMID: 35651540 PMCID: PMC9150024 SCOPUS ID: 2-s2.0-85131561638 06/03/2022       1 Citation
  • Progressive nodular histiocytosis with dramatic response to cobimetinib. (Berce PC, Cardwell L, Essenmacher AN, Michaelis LC, Wanat KA) JAAD Case Rep 2022 Apr;22:110-113 PMID: 35372654 PMCID: PMC8971330 SCOPUS ID: 2-s2.0-85127240995 04/05/2022       1 Citation
  • Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies. (Mohan M, Nagavally S, Shah N NN, Michaelis L, Chhabra S, Souza AD, Abedin S, Runaas L, Guru Murthy GS, Longo W, Hamadani M, Dhakal B, Hari P, Fenske TS) Clin Lymphoma Myeloma Leuk 2022 Jul;22(7):e495-e497 PMID: 35148976 PMCID: PMC8767926 SCOPUS ID: 2-s2.0-85132179962 02/13/2022       2 Citations
  • Is there an optimal adjunct therapy to traditional cytotoxic induction? (Michaelis LC) Best Pract Res Clin Haematol 2021 Dec;34(4):101326 PMID: 34865698 SCOPUS ID: 2-s2.0-85118977047 12/07/2021       1 Citation
  • Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia. (Pollyea DA, Barrett J, DiNardo CD, Michaelis LC, Roboz GJ, Le RQ, Norsworthy KJ, de Claro RA, Theoret MR, Pazdur R) Clin Cancer Res 2022 Mar 01;28(5):816-820 PMID: 34753779 SCOPUS ID: 2-s2.0-85125723561 11/11/2021       2 Citations
  • Avapritinib in the Treatment of Systemic Mastocytosis: an Update. (Below S, Michaelis LC) Curr Hematol Malig Rep 2021 Oct;16(5):464-472 PMID: 34580817 SCOPUS ID: 2-s2.0-85115791431 09/29/2021       3 Citations
  • The next wave: immunizing the immunosuppressed. (Michaelis LC) Blood 2021 Sep 02;138(9):746-747 PMID: 34473235 PMCID: PMC8411867 SCOPUS ID: 2-s2.0-85115000323 09/03/2021       1 Citation
  • Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review. (Chang Y, Guyatt GH, Teich T, Dawdy JL, Shahid S, Altman JK, Stone RM, Sekeres MA, Mukherjee S, LeBlanc TW, Abel GA, Hourigan CS, Litzow MR, Michaelis LC, Alibhai SMH, Desai P, Buckstein R, MacEachern J, Brignardello-Petersen R) PLoS One 2021;16(3):e0249087 PMID: 33784346 PMCID: PMC8009379 SCOPUS ID: 2-s2.0-85103594682 03/31/2021       1 Citation
  • Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia. (Mushtaq MU, Harrington AM, Chaudhary SG, Michaelis LC, Carlson KB, Abedin S, Runass L, Callander NS, Fallon MJ, Juckett M, Hall AC, Hematti P, Mattison RJ, Atallah EL, Guru Murthy GS) Leuk Lymphoma 2021 Jan;62(1):158-166 PMID: 32951486 SCOPUS ID: 2-s2.0-85091139710 09/22/2020       10 Citations
  • Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. (Uy GL, Aldoss I, Foster MC, Sayre PH, Wieduwilt MJ, Advani AS, Godwin JE, Arellano ML, Sweet KL, Emadi A, Ravandi F, Erba HP, Byrne M, Michaelis L, Topp MS, Vey N, Ciceri F, Carrabba MG, Paolini S, Huls GA, Jongen-Lavrencic M, Wermke M, Chevallier P, Gyan E, Récher C, Stiff PJ, Pettit KM, Löwenberg B, Church SE, Anderson E, Vadakekolathu J, Santaguida M, Rettig MP, Muth J, Curtis T, Fehr E, Guo K, Zhao J, Bakkacha O, Jacobs K, Tran K, Kaminker P, Kostova M, Bonvini E, Walter RB, Davidson-Moncada JK, Rutella S, DiPersio JF) Blood 2021 Feb 11;137(6):751-762 PMID: 32929488 PMCID: PMC7885824 SCOPUS ID: 2-s2.0-85100648634 09/16/2020       185 Citations
  • American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. (Sekeres MA, Guyatt G, Abel G, Alibhai S, Altman JK, Buckstein R, Choe H, Desai P, Erba H, Hourigan CS, LeBlanc TW, Litzow M, MacEachern J, Michaelis LC, Mukherjee S, O'Dwyer K, Rosko A, Stone R, Agarwal A, Colunga-Lozano LE, Chang Y, Hao Q, Brignardello-Petersen R) Blood Adv 2020 Aug 11;4(15):3528-3549 PMID: 32761235 PMCID: PMC7422124 SCOPUS ID: 2-s2.0-85090204128 08/08/2020       109 Citations
  • Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study. (George G, Rezazadeh A, Zook F, Pearl N, McCoy C, Carlson K, Runaas L, Abedin S, Guru Murthy GS, Michaelis LC, Atallah E, Baumann-Kreuziger L) Leuk Res 2020 Jul;94:106368 PMID: 32442786 SCOPUS ID: 2-s2.0-85084755644 05/23/2020       4 Citations
  • From Theory to Practice: Implementation of Strategies to Reduce Acute Care Visits in Patients With Cancer. (Daly B, Michaelis LC, Sprandio JD, Kapke JT, Narra RK, Malosh E, Zervoudakis A, Holland J, Zablocki M) Am Soc Clin Oncol Educ Book 2020 May;40:85-94 PMID: 32421450 05/19/2020    
  • Survival following allogeneic transplant in patients with myelofibrosis. (Gowin K, Ballen K, Ahn KW, Hu ZH, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, Gupta V, Hobbs G, Jain T, Kandarpa M, Komrokji R, Kuykendall AT, Luber K, Masarova L, Michaelis LC, Patches S, Pariser AC, Rampal R, Stein B, Talpaz M, Verstovsek S, Wadleigh M, Agrawal V, Aljurf M, Angel Diaz M, Avalos BR, Bacher U, Bashey A, Beitinjaneh AM, Cerny J, Chhabra S, Copelan E, Cutler CS, DeFilipp Z, Gadalla SM, Ganguly S, Grunwald MR, Hashmi SK, Kharfan-Dabaja MA, Kindwall-Keller T, Kröger N, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Nathan S, Nishihori T, Olsson RF, Pawarode A, Rowe JM, Savani BN, Savoie ML, Seo S, Solh M, Tamari R, Verdonck LF, Yared JA, Alyea E, Popat U, Sobecks R, Scott BL, Nakamura R, Mesa R, Saber W) Blood Adv 2020 May 12;4(9):1965-1973 PMID: 32384540 PMCID: PMC7218417 SCOPUS ID: 2-s2.0-85086108920 05/10/2020       55 Citations
  • Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. (Garcia-Manero G, Griffiths EA, Steensma DP, Roboz GJ, Wells R, McCloskey J, Odenike O, DeZern AE, Yee K, Busque L, O'Connell C, Michaelis LC, Brandwein J, Kantarjian H, Oganesian A, Azab M, Savona MR) Blood 2020 Aug 06;136(6):674-683 PMID: 32285126 PMCID: PMC7414597 SCOPUS ID: 2-s2.0-85089170147 04/15/2020       139 Citations
  • BCL-2 inhibition and AML: can we best Darwin? (Michaelis LC) Blood 2020 Mar 12;135(11):781-782 PMID: 32163555 SCOPUS ID: 2-s2.0-85081912295 03/13/2020       2 Citations
  • Improving Outcomes of Acute Promyelocytic Leukemia in the Current Era: Analysis of the SEER Database. (Guru Murthy GS, Szabo A, Michaelis L, Carlson KS, Runaas L, Abedin S, Atallah E) J Natl Compr Canc Netw 2020 Feb;18(2):169-175 PMID: 32023530 SCOPUS ID: 2-s2.0-85079065513 02/06/2020       20 Citations
  • Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. (Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN) Biol Blood Marrow Transplant 2020 May;26(5):893-901 PMID: 31982543 SCOPUS ID: 2-s2.0-85080146585 01/27/2020       12 Citations
  • A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias. (Lin TL, Newell LF, Stuart RK, Michaelis LC, Rubenstein E, Pentikis HS, Callahan T, Alvarez D, Liboiron BD, Mayer LD, Wang Q, Banerjee K, Louie AC) Cancer Chemother Pharmacol 2019 Jul;84(1):163-173 PMID: 31098682 PMCID: PMC6562048 SCOPUS ID: 2-s2.0-85066040714 05/18/2019       10 Citations
  • Preface. (Michaelis LC) Best Pract Res Clin Haematol 2019 Mar;32(1):1-2 PMID: 30927968 SCOPUS ID: 2-s2.0-85063367341 04/01/2019    
  • An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. (Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, Faderl S, Harb W, Kantarjian H, Lowder J, Oganesian A, Azab M, Garcia-Manero G) Lancet Haematol 2019 Apr;6(4):e194-e203 PMID: 30926081 SCOPUS ID: 2-s2.0-85063237060 03/31/2019       88 Citations
  • Venetoclax in AML: aiming for "just right". (Michaelis LC) Blood 2019 Jan 03;133(1):3-4 PMID: 30606807 SCOPUS ID: 2-s2.0-85059500759 01/05/2019       3 Citations
  • Cytotoxic therapy in acute myeloid leukemia: not quite dead yet. (Michaelis LC) Hematology Am Soc Hematol Educ Program 2018 Nov 30;2018(1):51-62 PMID: 30504291 PMCID: PMC6246033 SCOPUS ID: 2-s2.0-85058762393 12/07/2018       6 Citations
  • Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia. (Michaelis LC, Klepin HD, Walter RB) Expert Opin Pharmacother 2018 Jun;19(8):865-882 PMID: 29697000 SCOPUS ID: 2-s2.0-85047964670 04/27/2018       14 Citations
  • Early Fluorescence in situ Hybridization Assessment during Acute Myeloid Leukemia Induction Chemotherapy. (Schneidewend R, Hosking P, Brazauskas R, Peterson J, Beaudin C, Michaelis L, Atallah E, Hari P, Carlson K) Acta Haematol 2018;139(3):171-175 PMID: 29597188 PMCID: PMC6388419 SCOPUS ID: 2-s2.0-85045039013 03/30/2018    
  • Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). (Advani AS, Li H, Michaelis LC, Medeiros BC, Liedtke M, List AF, O'Dwyer K, Othus M, Erba HP, Appelbaum FR) Leuk Res 2018 Apr;67:17-20 PMID: 29407182 PMCID: PMC6574123 SCOPUS ID: 2-s2.0-85041670448 02/07/2018       23 Citations
  • Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. (Walter RB, Michaelis LC, Othus M, Uy GL, Radich JP, Little RF, Hita S, Saini L, Foran JM, Gerds AT, Klepin HD, Hay AE, Assouline S, Lancet JE, Couban S, Litzow MR, Stone RM, Erba HP) Am J Hematol 2018 Feb;93(2):E49-E52 PMID: 29164656 PMCID: PMC5760282 SCOPUS ID: 2-s2.0-85037372411 11/23/2017       13 Citations
  • Current challenges in the management of essential thrombocythemia. (Kleman A, Singavi AK, Michaelis LC) Clin Adv Hematol Oncol 2017 Oct;15(10):773-783 PMID: 29040257 SCOPUS ID: 2-s2.0-85033804556 10/19/2017       8 Citations
  • A Fatal Case of Erdheim-Chester Disease with Hepatic Involvement. (Balasubramanian G, Modiri A, Affi M, Hagen CE, Batdorf B, Oshima K, Michaelis L, Saeian K) ACG Case Rep J 2017;4:e95 PMID: 28798943 PMCID: PMC5541758 08/12/2017    
  • Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. (Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KS, Hamadani M, Fenske TS, Hari P, Atallah E, Dhakal B) Am J Hematol 2017 Sep;92(9):E563-E565 PMID: 28631379 SCOPUS ID: 2-s2.0-85021972988 06/21/2017       4 Citations
  • Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. (Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M) Biol Blood Marrow Transplant 2017 Aug;23(8):1295-1302 PMID: 28412518 SCOPUS ID: 2-s2.0-85019639994 04/17/2017       8 Citations
  • Risk stratification in myelofibrosis: the quest for simplification. (Michaelis LC) Haematologica 2017 Jan;102(1):2-3 PMID: 28040786 PMCID: PMC5210226 SCOPUS ID: 2-s2.0-85008319087 01/04/2017       4 Citations
  • Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. (Hanif A, Hari PN, Atallah E, Carlson KS, Pasquini MC, Michaelis LC) Bone Marrow Transplant 2016 Apr;51(4):617-8 PMID: 26726940 SCOPUS ID: 2-s2.0-84953295752 01/05/2016       17 Citations
  • Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. (Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V) Biol Blood Marrow Transplant 2016 Mar;22(3):432-40 PMID: 26493563 PMCID: PMC5030817 SCOPUS ID: 2-s2.0-84950996639 10/24/2015       114 Citations
  • Recent developments in the treatment of older individuals with acute myeloid leukemia: 2014. (Michaelis LC, Erba HP) Curr Opin Hematol 2015 Mar;22(2):108-15 PMID: 25603478 SCOPUS ID: 2-s2.0-84923248544 01/21/2015       6 Citations
  • Mechanisms of thrombogenesis in polycythemia vera. (Kroll MH, Michaelis LC, Verstovsek S) Blood Rev 2015 Jul;29(4):215-21 PMID: 25577686 PMCID: PMC4466074 SCOPUS ID: 2-s2.0-84937164094 01/13/2015       56 Citations
  • Hematopoietic stem cell transplantation in older persons: respecting the heterogeneity of age. (Michaelis LC, Hamadani M, Hari PN) Expert Rev Hematol 2014 Jun;7(3):321-4 PMID: 24785114 SCOPUS ID: 2-s2.0-84900867182 05/03/2014       9 Citations
  • Cutis verticis gyrata. (Walshauser MA, Birch NW, Michaelis LC) Am J Med Sci 2014 Aug;348(2):176 PMID: 23328837 SCOPUS ID: 2-s2.0-84905094221 01/19/2013       3 Citations
  • Salvage second hematopoietic cell transplantation in myeloma. (Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Mikhael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P, Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research) Biol Blood Marrow Transplant 2013 May;19(5):760-6 PMID: 23298856 PMCID: PMC3816739 SCOPUS ID: 2-s2.0-84876327529 01/10/2013       96 Citations
  • Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. (Stein BL, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D, Michaelis L, Odenike O, Rademaker A, Zakarija A, McMahon B, Spivak JL, Moliterno AR) Leuk Lymphoma 2013 Sep;54(9):1989-95 PMID: 23245211 SCOPUS ID: 2-s2.0-84879104781 12/19/2012       62 Citations
  • Hemoglobin levels triggering erythropoiesis-stimulating agent therapy in patients with cancer: the shift after United States Food and Drug Administration policy changes. (Stroupe KT, Tarlov E, Lee TA, Weichle TW, Zhang QL, Michaelis LC, Ozer H, Durazo-Arvizu R, Browning MM, Hynes DM) Pharmacotherapy 2012 Nov;32(11):988-97 PMID: 23108695 SCOPUS ID: 2-s2.0-84871581983 10/31/2012       5 Citations
  • Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002-2008. (Tarlov E, Stroupe KT, Lee TA, Weichle TW, Zhang QL, Michaelis LC, Ozer H, Browning MM, Hynes DM) Support Care Cancer 2012 Aug;20(8):1649-57 PMID: 21935718 SCOPUS ID: 2-s2.0-84863989608 09/22/2011       14 Citations
  • Rearrangements of the MLL gene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding. (Le H, Singh S, Shih SJ, Du N, Schnyder S, Loredo GA, Bien C, Michaelis L, Toor A, Diaz MO, Vaughan AT) Genes Chromosomes Cancer 2009 Sep;48(9):806-15 PMID: 19530238 PMCID: PMC2764312 SCOPUS ID: 2-s2.0-68549135307 06/17/2009       33 Citations
  • Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. (Nand S, Godwin J, Smith S, Barton K, Michaelis L, Alkan S, Veerappan R, Rychlik K, Germano E, Stiff P) Leuk Lymphoma 2008 Nov;49(11):2141-7 PMID: 19021057 SCOPUS ID: 2-s2.0-57049171822 11/21/2008       59 Citations
  • Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. (Gordon MK, Sher D, Karrison T, Kebriaei P, Chuang K, Zhang Y, McDonnell D, Artz A, Godley L, Odenike O, Rich E, Michaelis L, Thirman MJ, Wickrema A, van Besien K, Larson RA, Stock W) Leuk Lymphoma 2008 Mar;49(3):531-7 PMID: 18297531 SCOPUS ID: 2-s2.0-39749131562 02/26/2008       8 Citations
  • Chimerism does not predict for outcome after alemtuzumab based conditioning. (Michaelis L, Lin S, Joseph L, Artz AS, Kline J, Pollyea D, Stock W, Rich E, Collins-Jones D, Casey B, Del Cerro P, van Besien K) Bone Marrow Transplant 2007 Jul;40(2):181 PMID: 17502895 SCOPUS ID: 2-s2.0-34447284249 05/16/2007       7 Citations
  • Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties. (Michaelis LC, Ratain MJ) Clin Cancer Res 2007 Apr 15;13(8):2400-5 PMID: 17438099 SCOPUS ID: 2-s2.0-34247860864 04/18/2007       27 Citations
  • Measuring response in a post-RECIST world: from black and white to shades of grey. (Michaelis LC, Ratain MJ) Nat Rev Cancer 2006 May;6(5):409-14 PMID: 16633367 SCOPUS ID: 2-s2.0-33646357786 04/25/2006       165 Citations
  • Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing? (Stadler WM, Michaelis LC, Ratain MJ) J Clin Oncol 2005 Nov 01;23(31):8124-5; author reply 8125-6 PMID: 16258115 SCOPUS ID: 2-s2.0-32944469067 11/01/2005       2 Citations
    • Last update: 02/22/2024